Literature DB >> 12187164

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations.

Peter B Bach1, Edward Guadagnoli, Deborah Schrag, Nicola Schussler, Joan L Warren.   

Abstract

Users of the linked SEER-Medicare database commonly perform analyses that focus on the complex interactions among patient characteristics, cancer treatments, and outcomes. The authors review the source and scope of the patient-specific data elements, with a focus on three domains--demographic characteristics, socioeconomic characteristics, and survival status. They offer some concrete recommendations regarding the use of these data elements. In particular, they describe analyses that provide an estimate of the accuracy of the sex and age variables, and raise some cautionary notes about race and ethnicity variables. The authors describe the available measures of socioeconomic status, and recommend, with some caveats, the use of median income measures as a proxy for socioeconomic status. Finally, they describe the available data on date of death, and explain why confidence in these measures is justified.

Entities:  

Mesh:

Year:  2002        PMID: 12187164     DOI: 10.1097/00005650-200208001-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  101 in total

1.  Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.

Authors:  Christina D Mack; William Carpenter; Anne-Marie Meyer; Hanna Sanoff; Til Stürmer
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

2.  Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.

Authors:  Rajwanth R Veluswamy; Grace Mhango; Marcelo Bonomi; Alfred I Neugut; Dawn L Hershman; Melissa D Aldridge; Juan P Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2013-12

3.  Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma.

Authors:  Mario Mandalà; Gian Lorenzo Imberti; Dario Piazzalunga; Maurizio Belfiglio; Giuseppe Lucisano; Roberto Labianca; Lorenzo Marchesi; Barbara Merelli; Silvana Robone; Paola Poletti; Laura Milesi; Carlo Tondini
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

4.  Estimating incident population distribution from prevalent data.

Authors:  Kwun Chuen Gary Chan; Mei-Cheng Wang
Journal:  Biometrics       Date:  2012-02-07       Impact factor: 2.571

5.  Race and surgical mortality in the United States.

Authors:  F L Lucas; Therese A Stukel; Arden M Morris; Andrea E Siewers; John D Birkmeyer
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

6.  Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.

Authors:  Christopher S Saigal; Christopher M Deibert; Julie Lai; Matthias Schonlau
Journal:  Urol Oncol       Date:  2008-12-12       Impact factor: 3.498

7.  There goes the neighborhood effect: bias owing to nondifferential measurement error in the construction of neighborhood contextual measures.

Authors:  Stephen J Mooney; Catherine A Richards; Andrew G Rundle
Journal:  Epidemiology       Date:  2014-07       Impact factor: 4.822

8.  Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study.

Authors:  Omar Hyder; Rebecca M Dodson; Hari Nathan; Joseph M Herman; David Cosgrove; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-09-13       Impact factor: 6.113

9.  Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.

Authors:  Marian E Gornick; Paul W Eggers; Gerald F Riley
Journal:  Health Serv Res       Date:  2004-10       Impact factor: 3.402

10.  Hospital volume is associated with survival but not multimodality therapy in Medicare patients with advanced head and neck cancer.

Authors:  Arun Sharma; Stephen M Schwartz; Eduardo Méndez
Journal:  Cancer       Date:  2013-03-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.